Table 2.
Comparison of age-standardized incidence, mortality, prevalence, YLL, YLD, and DALY rates of lymphoma between in China and in the world, 2016
| Variable (per 100,000) | Hodgkin’s lymphoma | Non-Hodgkin’s lymphoma | ||
|---|---|---|---|---|
| China | World | China | World | |
| ASIR | 0.46 (0.36–0.57) | 1.33 (1.16–1.56) | 4.29 (3.61–4.52) | 6.34 (6.24–6.44) |
| ASMR | 0.19 (0.16–0.25) | 0.43 (0.36–0.50) | 2.45 (2.06–2.61) | 3.24 (3.18–3.30) |
| ASPR | 1.75 (1.35–2.13) | 8.63 (7.48–10.29) | 14.94 (12.64–15.82) | 30.75 (30.28–31.23) |
| Age-standardized YLLs | 5.77 (4.79–7.61) | 17.66 (14.77–20.84) | 69.27 (58.65–73.96) | 89.56 (87.26–91.73) |
| Age-standardized YLDs | 0.18 (0.13–0.26) | 0.66 (0.46–0.90) | 1.40 (0.96–1.89) | 2.51 (1.83–3.29) |
| Age-standardized DALYs | 5.95 (4.94–7.83) | 18.32 (15.36–21.62) | 70.67 (59.87–75.38) | 92.07 (89.58–94.40) |
ASIR age-standardized incidence rate, ASMR age-standardized mortality rate, ASPR age-standardized prevalence rate, DALYs disability-adjusted life years, YLDs years lived with disability, YLLs years of life lost
Data in parentheses are 95% uncertainty intervals